AD/PD 2025

April 1-5, 2025
Vienna Austria


– SILVER SPONSOR –

Visit Conference Site

Booth 22C

Product Theater

April 03 | 10:40-11:10 AM

pTau and Beyond. High-sensitivity & multiplex detection of biofluid-based biomarkers with NULISA.

Nicholas Ashton, PhD
Sr. Director, Fluid Biomarker Program
Banner Health

Alex Forrest-Hay
Senior VP of Sales
Alamar Biosciences

Posters and Orals

Poster Session 1
Wednesday, April 2 – Thursday, April 3

  • 380
    PLASMA VS. SERUM: WHICH IS BETTER FOR PROTEOMIC BLOOD BIOMARKER ANALYSIS? EVALUATION OF THE NOVEL NULISA PLATFORM
    • Marissa Farinas1 , Yijun Chen2 , Xuemei Zeng1 , Tara Lafferty1 , Anuradha Sehrawat1, Michel Nafash1 , Ally Albert1 , Oscar Lopez3 , Thomas Karikari1
      1University of Pittsburgh Medical Center, Psychiatry, Pittsburgh, United States of America, 2University of Pittsburgh, Chemistry, Pittsburgh, United States of America, 3University of Pittsburgh, Neurology, Pittsburgh, United States of America
  • 358
    INVESTIGATION OF PLASMA BIOMARKERS FOR THE DETECTION OF AUTOPSY CONFIRMED COPATHOLOGIES IN ALZHEIMER’S DISEASE – On-demand Oral
    • Jennifer Cooper1 , Andrew Agbay1 , Sophie Stukas1 , Naomi Futhey1 , Imogene Scott1 , Ian Mackenzie1 , Veronica Hirsch-Reinshagen1 , Robin Hsiung1 , Cheryl Wellington2 1University of British Columbia, Pathology And Laboratory Medicine, Vancouver, Canada, 2The University of British Columbia, Pathology And Laboratory Medicine, Vancouver, Canada
  • 383
    IDENTIFYING CIRCULATING PROTEIN SIGNATURES FOR MILD COGNITIVE IMPAIRMENT IN PAIRED CSF AND PLASMA
    • Aida Kamalian1 , Polina Shichkova2 , Marco Tognetti2 , Christopher Below2 , Sara Ho1 , Roland Bruderer2 , Lukas Reiter2 , Yuehan Feng2 , Michael Lutz3 , Abhay Moghekar1
      1 Johns Hopkins University School of Medicine, Department Of Neurology, Baltimore, United States of America, 2Biognosys AG, Schlieren, Switzerland, 3Duke University School of Medicine, Department Of Neurology, Durham, United States of America
  • 506
    PROTEOMIC ANALYSIS OF NEURONAL RESPONSES TO COMMON VIRAL INFECTIONS RELATED TO NEURODEGENERATION
    • Jacob Epstein1 , Ziyi Li1 , Shih-Heng Chen2 , Ying Hao1 , Daniel Ramos1 , Joanne Damborsky3 , Jerrel Yakel3 , Cory Weller1 , Kate Andersh1 , Caroline Pantazis1 , Andrew Singleton1 , Negin Martin2 , Andy Qi1
      1NIH, Center For Alzheimer’s And Related Dementias (nia/card), Bethesda, United States of America, 2Viral Vector Core Facility, National Institute of Environmental Health Sciences, Durham, United States of America, 3Laboratory of Neurobiology, NIEHS, NIH, Durham, United States of America
  • 651
    PLASMA P-TAU217 VERSUS SERUM P-TAU217: ARE THEY EQUIVALENT? ASSESSMENT OF THREE COMMERCIAL ASSAYS
    • Ally Albert1 , Yijun Chen2 , Anuradha Sehrawat1 , Xuemei Zeng3 , Tara Lafferty3 , Michel Nafash1 , Marissa Farinas1 , Ann Malia4 , Rebecca Roush4 , Ann Cohen4 , Oscar Lopez5 , Thomas Karikari1
      1University of Pittsburgh Medical Center, Psychiatry, Pittsburgh, United States of America, 2University of Pittsburgh, Department Of Chemistry, Pittsburgh, United States of America, 3University of Pittsburgh, Psychiatry, Pittsburgh, United States of America, 4University of Pittsburgh, Department Of Psychiatry, Pittsburgh, United States of America, 5University of Pittsburgh, Neurology, Pittsburgh, United States of America

Poster Session 2
Friday, April 4 – Saturday, April 5

  • 143
    HIGH-PLEX PROTEOMIC CHARACTERIZATION OF PRECLINICAL MODELS WITH THE NULISASEQ 120-PLEX MURINE PANEL
    • Xiao-Jun Ma1 , Li Wang1 , Hiyuen Ji1 , Wai Hang Cheng2 , Jianjia Fan2 , Tetiana Poliakova2 , Carlos Barron2 , Andrew Agbay2 , Shweta Iyengar1 , Sean Kim1 , Niyati Jhaveri1 , Xialoei Qiu1 , Bingqing Zhang1 , Cheryl Wellington2 , Yuling Luo1
      1Alamar Biosciences, Fremont, United States of America, 2The University of British Columbia, Pathology And Laboratory Medicine, Vancouver, Canada
  • 352
    COMPARISON OF CEREBROSPINAL FLUID PTAU, PTAU/A    Β38, AΒ42/40, AND AΒ42/38 IN PREDICTING AMYLOID-PET POSITIVITY – On-demand Oral
    • Yansheng Zheng1 , Joseph Therriault1 , Arthur Macedo1 , Yi-Ting Wang1 , Nesrine Rahmouni1 , Brandon Hall1 , Seyyed Ali Hosseini1 , Stijn Servaes1 , Etienne Aumont1 , Gleb Bezgin1 , Tevy Chan1 , Jenna Stevenson1 , Jaime Fernandez-Arias1 , Lydia Trudel1 , Kely Quispialaya-Socualaya1 , Lujia Wan1 , Thomas Karikari2 , Tharick Pascoal3 , Andrea Benedet4 , Nicholas Ashton5 , Kaj Blennow6 , Henrik Zetterberg5 , Paolo Vitali1 , Gerhard Multhaup7 , Pedro Rosa-Neto1 , Serge Gauthier8
      1McGill University, Neurology And Neurosurgery, Montreal, Canada, 2Department of Psychiatr, University of Pittsburgh, Pittsburgh, United States of America, 3University of Pittsburgh, Pittsburgh, United States of America, 4University of Gothenburg, Gothenburg, Sweden, 5Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, 6Gothenburg University, Göteborg, Sweden, 7Mcgill University, Pharmacology And Therapeutics, Montreal, Canada, 8McGill Research Centre for Studies in Aging, Translational Neuroimaging Laboratory, Montreal, Canada
  • 358
    IDENTIFICATION OF DIFFERENTIALLY ABUNDANT PROTEINS IN ALZHEIMER’S, SYNUCLEIN, AND VASCULAR PATHOLOGIES USING THE NULISA PROTEOMICS PLATFORM
    • Anna Orduña Dolado1 , Andrea Benedet2 , Gemma Salvadó1 , Shorena Janelidze1 , Niklas MattssonCarlgren1,3,4 , Nicholas Ashton5,6,7,8 , Oskar Hansson1,9
      1Lund University, Clinical Memory Research Unit, Department Of Clinical Sciences, Lund, Sweden, 2 Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Department Of Psychiatry And Neurochemistry, Göteborg, Sweden, 3Lund University, Clinical Sciences, Lund, Sweden, 4Lund University, Wallenberg Center For Molecular Medicine, Lund, Sweden, 5Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, 6Banner Alzheimer’s Institute and University of Arizona, Phoenix, United States of America, 7NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, United Kingdom, 8Stavanger University Hospital, Centre For Age-related Medicine (sesam), Stavanger, Norway, 9Skåne University Hospital, Memory Clinic, Malmö, Sweden
  • 496
    CNS PROTEOMICS IDENTIFY POTENTIAL BIOMARKERS OF ACUTE AND CHRONIC TRAUMATIC BRAIN INJURY.
    • Sarah Svirsky, David Okonkwo, Ava Puccio
      University of Pittsburgh, Neurological Surgery, Pitttsburgh, United States of America
  • 607
    EVALUATION OF 120 NEURODEGENERATIVE AND INFLAMMATORY PROTEINS IN DRIED BLOOD SPOTS AND PLASMA SPOTS FOR POPULATION-WIDE BIOMARKER SCREENING WITH NULISASEQ TAUPATHIES / IMAGING, BIOMARKERS, DIAGNOSTICS / CSF- AND BLOOD-BASED BIOMARKERS – On-demand Oral
    • Xiao-Jun Ma, Karl Garcia, Tsz Tam, Li Wang, Sean Kim, Niyati Jhaveri, Xialoei Qiu, Bingqing Zhang, Yuling Luo
      Alamar Biosciences, Fremont, United States of America
  • 614
    A MULTI-MODAL BLOOD-BASED BIOMARKER PANEL REVEALS ALTERED LYSOSOMAL IONIC CONTENT IN ALZHEIMER’S DISEASE TAUPATHIES / IMAGING, BIOMARKERS, DIAGNOSTICS / CSF, BLOOD, BODY FLUID BIOMARKERS – On Demand Oral
    • Souvik Modi, Shareefa Thekkan, Dhivya Venkat
      Esya Labs, R&d, London, United Kingdom
  • 619
    PROTEOMIC BIOMARKER PROFILING IN ALZHEIMER’S DISEASE AND RELATED DEMENTIAS USING NULISA TAUPATHIES / IMAGING, BIOMARKERS, DIAGNOSTICS / CSF, BLOOD, BODY FLUID BIOMARKERS
    • Ramiro Eduardo Rea Reyes1 , Rachael Wilson1 , Erin Jonaitis1,2 , Julie Oomens1 , Rachel Studer2 , Sanjay Asthana1 , Rebecca Langhough1,3 , Henrik Zetterberg1,4,5,6,7,8 , Sterling Jonhson3,9
      1University of Wisconsin-Madison, Wisconsin Alzheimer’s Disease Research Center, Madison, United States of America, 2University of Wisconsin-Madison, Wisconsin Alzheimer’s Institute, Madison, United States of America, 3University of Wisconsin, Wisconsin Alzheimer’s Institute, University Of Wisconsin School Of Medicine And Public Health, Madison, United States of America, 4Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong PRC, 5UCL Institute of Neurology, Department Of Neurodegenerative Disease, London, United Kingdom, 6Clinical Neurochemistry Laboratory, Mölndal, Sweden, 7The Sahlgrenska Academy at the University of Gothenburg,, Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, Mölndal, Sweden, 8UK Dementia Research Institute, London, United Kingdom, 9Wisconsin Alzheimer’s Disease Research Center, Madison, United States of America
Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.